GSK eyes nasal polyps use for Nucala after trial success

GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into compet

AstraZeneca on expanding its diabetes research franchise

AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.

AZ firms up immuno-oncology imaging deal with ImaginAb

BI opens second branch of digital lab in China

Boehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in July this year in China.

FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki

AstraZeneca: pharma needs to lead by example on sustainabili...

Paul Tunnah sat down with AstraZeneca's vice president of sustainability strategy and engagement Jim Massey to discuss how the global pharma company is embracing a green future.